Mavoglurant

Drug Profile

Mavoglurant

Alternative Names: AFQ-056

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Esters; Indoles; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Obsessive-compulsive disorders; Smoking withdrawal

Most Recent Events

  • 11 Aug 2017 Novartis plans a phase II trial for Cocaine abuse (NCT03242928)
  • 15 Dec 2016 Biomarkers information updated
  • 03 Oct 2016 Novartis plans a phase II trial for Fragile X Syndrome (Children) in USA (NCT02920892)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top